

Congenital Adrenal Hyperplasia (CAH)

Differential Diagnosis: Classic Congenital Adrenal Hyperplasia (CAH) caused by 21-hydroxylase deficiency; Non classic 21-hydroxylase deficiency caused by 21-hydroxylase deficiency; 11 beta-hydroxylase deficiency; prematurity.

Condition Description: CAH is caused by a deficiency of one of the enzymes required to synthesize cortisol in the adrenal glands. The most common type is 21-hydroxylase deficiency, resulting in impaired aldosterone and cortisol synthesis. 21-hydroxylase deficiency has two major forms: the salt wasting form, which can lead to adrenal crises, and the simple virilizing form. The simple virilizing form can cause virilization in biologic females. Non-classic 21-hydroxylase deficiency can cause hyperandrogenism and virilization later in childhood; it does not cause salt wasting adrenal crises, and may not be detected by newborn screening. 11- beta-hydroxylase deficiency may present in the newborn period with 17-OHP elevations.

**You Should Take the Following IMMEDIATE Actions
If The Infant Is Not Premature*:**

- Inform family of the newborn screening result.
- Ascertain clinical status (lethargy, vomiting, poor feeding).
- Consult with pediatric endocrinologist the same day.
- Immediately evaluate the newborn (lethargy, vomiting, ambiguous genitalia) and obtain serum electrolytes and glucose .
- Immediately transport to a hospital for further treatment in consultation with a pediatric endocrinologist.
- Initiate confirmatory/diagnostic testing and management, as recommended by the specialist.
- Provide the family with basic information about CAH. Educate the family about signs and symptoms of adrenal crises, including the need for urgent treatment.
- Report final diagnostic outcome to the state newborn screening program.

Diagnostic Evaluation: Adrenal steroid hormone panels: confirm the diagnosis.

ACTH stimulation testing, electrolyte changes with hyponatremia/hyperkalemia, and increased renin support the diagnosis. Molecular genetic testing : may be used to support a diagnosis of CAH and may help to determine the type of 21-hydroxylase deficiency.

Clinical Considerations: Newborns with the classic form of CAH are at risk for adrenal crises with illness, surgery, or trauma resulting in shock and death if untreated. Ambiguous genitalia can occur in biological females with CAH. A neonate with CAH may require lifelong adrenal hormone replacement therapy and often requires the care of a multidisciplinary team; therapy depends on the form of CAH.

*Premature infants have an increased rate of false positive test results; recommend

Reporting: Report diagnostic results to family and Kansas NBS program

If Congenital Hypothyroidism is confirmed, Kansas Law 65-180 through 65-183 requires reporting findings back to KDHE by a physician. Financial assistance for MPS II clinic services and treatments may be available to the family upon application to the Special Health Care Needs (SHCN) program. A SHCN application will be sent to the baby's address. Parents or physicians can call SHCN at (785) 296-1313 for more information.

Specialist Clinics:

Children's Mercy	Wichita, KS 316-500-8900
Wichita Endocrinology	Wichita, KS 316-777-6404
Children's Mercy (Topeka)	Topeka, KS 785- 600-3775
Rainbow Endocrinology	Lawrence, KS (785) 217-4827
Children's Mercy (Kansas City)	Kansas City, MO (816) 960-8803

This practice resource is designed primarily as an educational resource for medical geneticists and other clinicians to help them provide quality medical services. Adherence to this practice resource is completely voluntary and does not necessarily assure a successful medical outcome. This practice resource should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinician should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen. Clinicians are encouraged to document the reasons for the use of a particular procedure or test, whether or not it is in conformance with this practice resource. Clinicians also are advised to take notice of the date this practice resource was adopted, and to consider other medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.

© American College of Medical Genetics and Genomics, 2023 Content Updated: July 2024 (Funded in part through MCHB/HRSA/HHS grant #U22MC03957;#UH9MC30770; [National Coordinating Center for the Regional Genetics Networks](#))